Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis, which is a condition that develops red patches on the skin with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis. However, the joint problems can sometimes begin before skin patches appear. This condition develops when the immune system begins to attack healthy cells and tissue. The abnormal immune response causes inflammation in the joints as well as overproduction of skin cells.
Although it is unclear what triggers the self-harm from the immune system, it is likely that both genetic and environmental factors play a major role. One of the major factors that can exacerbate the development of psoriatic arthritis in obesity. According to OECD 2017 data, nearly 37% of the population of the United States was classified as obese and the report projects the population to increase to 47% by 2030. Hence, as the prevalence of obesity increases, the risk of psoriatic arthritis is expected to increase as well. Other factors like unhealthy lifestyle with indulgence in alcohol and smoking can also be attributed as risk factors for the development of psoriatic arthritis. Moreover, the development of new therapeutic methods is also expected to drive the growth of this market.
However, side effects from psoriatic arthritis therapeutic drugs and stringent regulations for drug approval are restraining the growth of this market.
Scope of the Report
Psoriatic Arthritis therapeutics includes drugs that help relieve pain, reduce inflammation, slow the progression of psoriatic arthritis or directly target parts immune system that triggers inflammation. In the report, a detailed analysis of the psoriatic arthritis therapeutics market is provided. The market is segmented by drug class, route of administration and geography.
Key Market Trends
Non-Steroidal Anti-Inflammatory Drugs (NSAID) are expected to hold a large share in Psoriatic Arthritis Therapeutics Market
NSAIDs are considered the first treatment option for psoriatic arthritis. For people diagnosed with psoriatic arthritis that show only mild symptoms of joint pain and swelling, NSAIDs are usually the first treatment option to consider. NSAIDs are also commonly used as an adjunct treatment in conjunction with biologics or disease-modifying antirheumatic drugs (DMAD) and to treat some severe cases. However, NSAIDs are not advised for people with severe psoriasis because it can cause skin flare-ups. However, with advancements in research and technology, safer NSAIDs have been developed with lesser side-effects. This is expected to help the growth of NSAIDs.
North America dominates the market
According to the 2017 center of disease control and prevention data, the prevalence of obesity has shown an increasing trend among adults in the United States. As per the report, the prevalence of obesity was nearly 30% in 2001-2002 among adults in the US. However, this ratio increased to nearly 40% in 2015-2016. According to OECD, Mexico has one of the highest prevalence of Obesity in the world. As obesity is one of the risk factors of psoriatic arthritis, the high and increasing prevalence is also expected to increase the prevalence of psoriatic arthritis in the future.
However, developed countries like the US and Canada have a structured healthcare system that has a fast adoption rate for newer drugs, therapies, and technologies. Hence, expenditure on psoriatic arthritis therapeutics is expected to increase with increasing prevalence in the future.
The majority of the key player involved in research and manufacturing of psoriatic arthritis therapy drugs are established in developed countries. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market growth.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support